A password will be e-mailed to you.

Licensed weed producer Tilray has formed a strategic alliance with Sandoz Canada One of Canada’s largest licensed weed producers has formed a strategic partnership with a major pharmaceutical company, marking the first — and much anticipated — foray of Big Pharma into the legal cannabis industry. Tilray, which is largely a British Columbia-based company but with headquarters in Toronto, announced early Monday morning that it had signed a binding letter of intent with Sandoz Canada, an affiliate of Sandoz International GmBh, which is part of the Swiss pharma giant Novartis AG. The agreement has two major components to it. First, it will see Tilray leveraging Sandoz’s know-how and internal sales force to educate Canadian pharmacists and physicians about Tilray’s medical cannabis products. Second, Sandoz and Tilray will partner up exclusively to develop new non-combustible cannabis products such as gel caps, edibles and sprays. And depending on future regulatory changes, Sandoz could eventually become the wholesale distributor of Tilray’s medical products to Canadian pharmacies and hospitals. Big Pharma has officially entered the Canadian cannabis industry

thumbnail courtesy of vice.com

No more articles